Analysis of the main functions and clinical applications of cabergoline

Cabergoline is an oral dopamine receptor agonist. It mainly inhibits the secretion of prolactin (PRL) in the anterior pituitary gland by selectively activating D2 dopamine receptors in the brain, thereby reducing serum prolactin levels. This mechanism makes it highly effective in hyperprolactinemia-related diseases, such as the improvement of symptoms such as galactorrhea, irregular menstruation, and infertility.

In clinical applications, cabergoline is commonly used to treat patients with pituitary prolactinoma. Prolactinoma is a common pituitary adenoma. Excessive secretion of prolactin can lead to menstrual disorders, infertility and galactorrhea in women, while men may suffer from decreased sexual function. By inhibiting prolactin secretion, cabergoline can significantly reduce blood prolactin levels and promote the reduction of pituitary tumor size, thus improving endocrine function and related symptoms.

In addition, cabergoline is also used in the treatment of non-neoplastic hyperprolactinemia. For example, some drugs (such as antipsychotics) or endocrine disorders may cause an increase in prolactin, causing galactorrhea or irregular menstruation. Cabergoline can effectively regulate prolactin levels, restore physiological endocrine balance, improve patients' quality of life, and reduce the risk of secondary diseases caused by high prolactin.

In clinical use, the dose and course of cabergoline need to be adjusted individually based on the patient's condition and blood prolactin level. It is usually recommended to start with a low dose, gradually increase to an effective dose, and regularly monitor serum prolactin and liver function indicators to ensure both efficacy and safety. Through scientific use, cabergoline can exert stable and reliable efficacy in the long-term management of prolactin-related diseases.

Reference materials:https://www.drugs.com/